ICLR
ICLR
IE0005711209
ICON plc
Loading chart...

Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Latest News

Related stocks

ERF.PA
ERF.PA • Luxembourg
EUROFINS SCIENT.
77.12 EUR
14.79B USD 1Y +21.5%
MTD
MTD • Switzerland
Mettler-Toledo International, I
1,549.99 USD
31.06B USD 1Y +15.1%
BIM.PA
BIM.PA • France
BIOMERIEUX
83.2 EUR
11B USD 1Y -28.4%
QGEN
QGEN • Netherlands
Qiagen N.V.
45.38 USD
9.37B USD 1Y -6.8%
1QGEN.MI
1QGEN.MI • Netherlands
QIAGEN
40.1 EUR
9.28B USD 1Y +0.2%
DIA.MI
DIA.MI • Italy
DIASORIN
77.42 EUR
4.27B USD 1Y -4.7%
LONN.SW
LONN.SW • Switzerland
LONZA N
572.2 CHF
48.15B USD 1Y +5.1%
VIMIAN.ST
VIMIAN.ST • Sweden
Vimian Group AB
35.75 SEK
1.89B USD 1Y +21.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
46.0% p.a.
Max Drawdown (5Y)
-76.9%
Sharpe Ratio (5Y)
-0.25
Beta Factor
1.24
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 172.8 (Elevated multiple compression risk)
Elevated Short-Term Volatility: 3Y volatility (51.4%) is noticeably higher than the 5Y average (46.0%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (46.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -76.9% in the extended horizon.
ende